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The RTS,S/AS01 vaccine is the ﬁ rst eﬀ ective malaria 
subunit vaccine tested in a phase 3 trial.1,2 The target 
antigen of the vaccine is circumsporozoite protein, 
a surface protein expressed only in sporozoites, the 
invasive stage of the malaria parasite, which are 
transmitted by infected mosquito bites to human beings 
and develop to other stages in the liver. The RTS,S/
AS01 vaccine acts solely at the pre-erythrocytic stages. 
In the phase 3 trial, the vaccine provided signiﬁ cant 
eﬃ  cacy against clinical malaria in diﬀ erent age groups 
in diﬀ erent transmission settings. Previous reports 
suggest that anti-circumsporozoite protein antibodies 
and circumsporozoite protein-speciﬁ c CD4-positive T 
cells were associated with protection from Plasmodium 
falciparum infection and clinical malaria.3,4 However, the 
duration of protection and determinants of immuno-
genicity after vaccination are unclear because of the lack 
of long-term follow-up in the phase 2 trials. 
In-depth analyses of the duration of protection is 
important for both the application of RTS,S/AS01 in 
Africa and for eﬀ orts to develop the next-generation 
of malaria vaccines based on circumsporozoite protein. 
In The Lancet Infectious Diseases, Michael White and 
colleagues report5 analyses of the determinants of 
immunogenicity induced by RTS,S/AS01, given with 
or without a booster, using data from 8922 African 
children aged 5–17 months and 6537 African infants 
aged 6–12 weeks in the pivotal phase 3 trial.6 To our 
knowledge, this is the ﬁ rst comprehensive analysis of the 
determinants of protective immunity of RTS,S/AS01. 
By comparison of anti-circumsporozoite protein 
antibody titres over time with individual follow-up data 
for episodes of clinical malaria, White and colleagues 
showed that the eﬃ  cacy proﬁ le of RTS,S/AS01 can be 
informed by measurements of anti-circumsporozoite 
protein antibodies, enabling estimation of the 
duration of protection. They estimated that an 
anti-circumsporozoite protein antibody titre of 
121 EU/mL could prevent 50% of infections. Waning 
antibody titres predict the duration of eﬃ  cacy against 
clinical malaria across diﬀ erent age categories and 
transmission intensities, and eﬃ  cacy wanes more 
rapidly at higher transmission intensity. The immune 
responses induced by RTS,S/AS01 vaccination and by 
natural infection are distinct. In low transmission areas, 
eﬃ  cacy against clinical malaria wanes because of the 
reduction in anti-circumsporozoite protein antibody 
titres. In high transmission areas, eﬃ  cacy against 
clinical malaria wanes more rapidly because of both the 
reduction in antibody titres and the lesser blood-stage 
immunity in vaccinated participants compared with 
control individuals. White and colleagues concluded 
that anti-circumsporozoite protein antibody titres 
are a surrogate of protection for the magnitude and 
duration of RTS,S/AS01 eﬃ  cacy.
The relation between anti-circumsporozoite 
protein antibody titres and eﬃ  cacy can be used 
to assess future iterations of RTS,S and second 
generation anti-circumsporozoite protein vaccines. 
Why antibody titres are not maintained is unknown, 
but could relate to the inability of sporozoites to 
naturally boost vaccine-induced antibody responses 
and the subsequent exposure to few sporozoites, or 
the polymorphic nature of the T-cell epitopes on the 
circumsporozoite protein.7 
This work shows the limits of anti-infection vaccines 
and highlights the importance of a blood-stage malaria 
vaccine that prevents disease caused by the blood-
stage parasite. Blood-stage vaccines induce protective 
immunity that is boosted by repeated natural parasite 
infection and the allelic polymorphism that hampered 
vaccine eﬃ  cacy8 in candidates such as apical membrane 
antigen 1 could be overcome by the identiﬁ cation 
of highly conserved blood-stage vaccine targets. 
Therefore, to improve the eﬃ  cacy of malaria vaccines, 
we suggest that addition of a conserved blood-stage 
vaccine component to RTS,S/AS01 as a multistage 
malaria vaccine is of paramount importance.
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High-dose inﬂ uenza vaccines make economic sense for 
older people
Inﬂ uenza causes a large and costly burden of disease 
in the USA and other high-income countries.1,2 Most 
hospital admissions and deaths are in adults aged 
65 years and older, who have the highest risk of 
inﬂ uenza-related complications. Inﬂ uenza vaccines do 
not seem to be particularly eﬃ  cacious in this group, 
although evidence is diﬃ  cult to interpret because of the 
shortage of relevant clinical trials.3,4
In 2009, the US Food and Drug Administration 
licensed Sanoﬁ  Pasteur’s Fluzone High-Dose vaccine, 
which contains four times more haemagglutinin 
antigen than the standard-dose vaccine. Findings 
from a head-to-head trial subsequently showed that 
the high-dose vaccine has a 24·2% higher eﬃ  cacy than 
the standard-dose equivalent.5 However, the high-
dose vaccine costs more than twice as much as the 
standard-dose vaccine, leading to calls for the cost-
eﬀ ectiveness of the vaccine to be evaluated.6 In The 
Lancet Infectious Diseases, Ayman Chit and colleagues7 
present a manufacturer-funded economic evaluation 
of data from the head-to-head trial, suggesting that 
administration of high-dose vaccines to adults aged 
65 years and older might actually be cost-saving 
compared with standard-dose vaccination, even after 
accounting for the diﬀ erences in cost.
The investigators examined two kinds of costs. First, 
they compared the costs of any drugs, emergency 
room visits, non-routine and urgent-care visits, and 
hospital admissions between participants receiving 
either standard-dose or high-dose vaccines. Second, 
they considered the cost of lost productivity because 
participants were not able to work while they were 
receiving health care. The average per-participant 
medical costs were US$116 lower (95% CI –36 to 264) 
and societal (total medical and productivity) costs 
$128 lower (–33 to 287) in the high-dose group than 
the standard-dose group. The reduction in costs in 
the high-dose group exceeded the additional cost 
of purchasing the more expensive vaccine. Indeed, 
the average averted costs of hospital care alone 
($136 per participant) were more than enough to 
pay for the extra cost of the vaccine ($19·75 per 
participant). The magnitude of predicted cost savings 
are such that if all 54 million adults aged 65 years or 
older who received inﬂ uenza vaccine in either the 2011–
12 or the 2012–13 seasons had received high-dose 
vaccines, the net savings to the US economy could have 
been $7·0 billion compared with if they had all received 
standard-dose vaccines..
Some caveats should be kept in mind. The original 
trial on which this evaluation was based was powered 
for an endpoint of laboratory-conﬁ rmed inﬂ uenza, 
irrespective of health-care use.5 Because medical 
attendances for inﬂ uenza are relatively rare, most of 
the outcomes examined did not diﬀ er signiﬁ cantly 
between the two groups. Fortunately, there was a 
signiﬁ cant diﬀ erence in hospital admissions, which 
were by far the most important outcome in terms of 
total costs. Indeed, the magnitude of the diﬀ erence 
is startling. There were 800 fewer admissions per 
